Augmentation of the RNA m6A reader signature is associated with poor survival by enhancing cell proliferation and EMT across cancer types.
Saved in:
| Title: | Augmentation of the RNA m6A reader signature is associated with poor survival by enhancing cell proliferation and EMT across cancer types. |
|---|---|
| Authors: | Oh J; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, 03080, Korea.; Department of Internal Medicine, Seoul National University Hospital, Seoul, 03080, Korea., Hwa C; School of Biosystem and Biomedical Science, College of Health Science, Korea University, Seoul, 02841, Korea.; BK21FOUR R&E Center for Learning Health Systems, Korea University, Seoul, 02841, Korea.; Department of Integrated Biomedical and Life Science, Korea University, Seoul, 02841, Korea., Jang D; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea., Shin S; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea., Lee SJ; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea., Kim J; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea., Lee SE; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea., Jung HR; Medical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, 03080, Korea., Oh Y; Medical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, 03080, Korea., Jang G; Medical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, 03080, Korea., Kwon O; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea.; Medical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, 03080, Korea., An JY; School of Biosystem and Biomedical Science, College of Health Science, Korea University, Seoul, 02841, Korea. joonan30@korea.ac.kr.; BK21FOUR R&E Center for Learning Health Systems, Korea University, Seoul, 02841, Korea. joonan30@korea.ac.kr., Cho SY; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, 03080, Korea. csybio@snu.ac.kr.; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea. csybio@snu.ac.kr.; Medical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, 03080, Korea. csybio@snu.ac.kr.; Cancer Research Institute, Seoul National University, Seoul, 03080, Korea. csybio@snu.ac.kr. |
| Source: | Experimental & molecular medicine [Exp Mol Med] 2022 Jul; Vol. 54 (7), pp. 906-921. Date of Electronic Publication: 2022 Jul 06. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 9607880 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2092-6413 (Electronic) Linking ISSN: 12263613 NLM ISO Abbreviation: Exp Mol Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
